---
title: "Rhinocort Allergy (budesonide): 2026 Review"
description: "OTC intranasal corticosteroid. The most extensive pregnancy-specific dataset of any INCS: first-line in pregnancy."
canonical: "https://allermi-site.vercel.app/reviews/rhinocort/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2026-04-21T00:00:00.000Z"
primaryKeyword: rhinocort review
ymylTier: high
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Pregnancy & Lactation
  credential: Editorial Pool
  sameAs: ["https://www.acog.org/", "https://mothertobaby.org/"]
citations: []
claims: [c-026, c-034, c-055, c-058]
---

## TL;DR

Rhinocort Allergy (budesonide 32 mcg/spray) is an OTC intranasal corticosteroid approved for ages 6 and older. Its main differentiator is pregnancy data: large Swedish registry studies of inhaled budesonide showed no increased birth defects, and both ACOG and the 2020 Joint Task Force identify budesonide as the preferred INCS in pregnancy. Considered compatible with breastfeeding.

import Claim from '../../components/Claim.astro';
import CitationList from '../../components/CitationList.astro';

<Claim id="c-034">Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older</Claim> <Claim id="c-026">The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy.</Claim> <Claim id="c-055">A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts.</Claim> <Claim id="c-058">Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding</Claim>

## Context & alternatives

In pregnancy, Rhinocort is unambiguously first-line; see the full [pregnancy-safe nasal spray guide](/demographic/pregnancy/) and the [breastfeeding compatibility summary](/demographic/breastfeeding/).

Outside of pregnancy and breastfeeding, for eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx personalized by a board-certified allergist. Allermi is not prescribed in pregnancy or breastfeeding. Not sure if you qualify (post-partum, for example)? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For chronic allergic congestion outside pregnancy, Rhinocort is also interchangeable with [Flonase](/reviews/flonase/) and [Nasonex](/reviews/nasonex/).

<CitationList items={[
 { id: "1", title: "DailyMed: Rhinocort SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd3fd05e-1c2e-4c1f-9c3b-66c59a9f1d2b", publisher: "FDA DailyMed" },
 { id: "2", title: "MotherToBaby: Budesonide fact sheet", url: "https://mothertobaby.org/fact-sheets/budesonide/", publisher: "OTIS" }
]} />